Summary & Overview
CPT 0153U: Insight TNBCtype™ Gene Expression Profiling for Triple-Negative Breast Cancer
CPT code 0153U designates the Insight TNBCtype™ proprietary laboratory assay from Insight Molecular Labs, a next-generation sequencing (NGS) gene expression profiling panel of 101 genes that provides triple-negative breast cancer (TNBC) subtyping. As a PLA code, 0153U applies to a single manufacturer-specific test and signals a specialized diagnostic service in precision oncology. Nationally, PLA codes like 0153U matter because they identify distinct commercial assays, inform coverage determinations, and affect billing clarity for advanced molecular diagnostics.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical purpose of the assay, typical sites where the service is provided, and the payer landscape covered in the analysis. The publication provides benchmarks for billing and utilization where available, notes on payer coverage patterns for proprietary molecular tests, and context on how PLA coding fits into clinical workflows for triple-negative breast cancer. Additional sections cover common modifier usage, associated administrative elements, and implications for laboratory service lines. Data not available in the input for specific coverage policies, ICD-10 pairings, or taxonomy mappings is explicitly noted where relevant.
Billing Code Overview
CPT code 0153U is a Proprietary Laboratory Analyses (PLA) code reported for the Insight TNBCtype™ test from Insight Molecular Labs. The test uses gene expression profiling by next-generation sequencing to analyze 101 genes with algorithmic interpretation and is reported as triple-negative breast cancer subtyping information.
Service type: Proprietary laboratory molecular diagnostic test (gene expression profiling by NGS)
Typical site of service: Clinical reference laboratory / specialty molecular diagnostics laboratory
Clinical & Coding Specifications
Clinical Context
A 52-year-old woman presents after routine imaging and biopsy confirming invasive triple-negative breast cancer (TNBC). Her oncology team orders the Insight TNBCtype™ genomic assay to profile tumor gene expression via next-generation sequencing of 101 genes to classify tumor subtype and inform clinical trial eligibility and systemic therapy selection. The test is performed on a formalin-fixed paraffin-embedded (FFPE) tumor specimen collected at the time of diagnostic core needle biopsy or surgical resection. The specimen is sent to Insight Molecular Labs with accompanying pathology and clinical history. The laboratory performs RNA extraction, next-generation sequencing, and algorithmic analysis to report TNBC subtype. Results are returned to the ordering medical oncologist and surgical pathology team to integrate into treatment planning and potential enrollment in targeted therapy trials. Typical site of service: outpatient hospital pathology/laboratory or independent reference laboratory; specimen collection occurs in ambulatory surgery center, hospital outpatient department, or physician office during biopsy or surgery.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the professional interpretation component if the performing laboratory separates technical and professional components and the ordering provider bills for interpretation. |